| The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood–brain barrier (BBB) permeability K Lingineni, V Belekar, SR Tangadpalliwar, P Garg Molecular diversity 21, 355-365, 2017 | 61 | 2017 |
| Classification of breast cancer resistant protein (BCRP) inhibitors and non-inhibitors using machine learning approaches V Belekar, K Lingineni, P Garg Combinatorial Chemistry & High Throughput Screening 18 (5), 476-485, 2015 | 21 | 2015 |
| Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy K Lingineni, V Aggarwal, JF Morales, DJ Conrado, D Corey, C Vong, ... CPT: Pharmacometrics & Systems Pharmacology 11 (3), 318-332, 2022 | 17 | 2022 |
| Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype‐Derived Activity Scores CD Thomas, SA Mosley, S Kim, K Lingineni, N El Rouby, TY Langaee, ... CPT: Pharmacometrics & Systems Pharmacology 9 (12), 678-685, 2020 | 15 | 2020 |
| Quantitative assessment of levonorgestrel binding partner interplay and drug‐drug interactions using physiologically based pharmacokinetic modeling B Cicali, K Lingineni, R Cristofoletti, T Wendl, J Hoechel, H Wiesinger, ... CPT: Pharmacometrics & Systems Pharmacology 10 (1), 48-58, 2021 | 11 | 2021 |
| Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate N Farhan, R Cristofoletti, S Basu, S Kim, K Lingineni, S Jiang, JD Brown, ... CPT: Pharmacometrics & Systems Pharmacology 10 (3), 199-210, 2021 | 9 | 2021 |
| Evaluating the clinical impact of formulation variability: a metoprolol extended‐release case study S Kim, VD Sharma, K Lingineni, N Farhan, L Fang, L Zhao, JD Brown, ... The Journal of Clinical Pharmacology 59 (9), 1266-1274, 2019 | 9 | 2019 |
| Quantitative Benefit–Risk Assessment of P‐gp–Mediated Drug–Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment K Lingineni, N Farhan, S Kim, R Cristofoletti, LA Gordon, P Kumar, ... Clinical Pharmacology & Therapeutics 109 (1), 193-200, 2021 | 8 | 2021 |
| Predicting cost‐effectiveness of generic vs. brand dabigatran using pharmacometric estimates among patients with atrial fibrillation in the United States CY Wang, PN Pham, S Kim, K Lingineni, S Schmidt, V Diaby, J Brown Clinical and Translational Science 13 (2), 352-361, 2020 | 6 | 2020 |
| Determining the exposure threshold for levonorgestrel efficacy using an integrated model based meta‐analysis approach K Lingineni, A Chaturvedula, B Cicali, R Cristofoletti, T Wendl, J Hoechel, ... Clinical Pharmacology & Therapeutics 111 (2), 509-518, 2022 | 5 | 2022 |
| Development and verification of a body weight–directed disease trial model for glucose homeostasis N Farhan, I Gebert, Y Xing, K Wieser, K Lingineni, X Ma, JY Chien, ... The Journal of Clinical Pharmacology 61 (2), 234-243, 2021 | 3 | 2021 |
| Development of a Translational Exposure‐Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug Products B Cicali, L Da Silva, A Sarayani, K Lingineni, M Pressly, S Kim, T Wendl, ... Clinical Pharmacology & Therapeutics 112 (4), 909-916, 2022 | 2 | 2022 |
| A randomized, cross‐over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence SA Mosley, S Kim, N El Rouby, K Lingineni, VV Esteban, Y Gong, Y Chen, ... Clinical and Translational Science 15 (7), 1764-1775, 2022 | 1 | 2022 |
| P146 A clinical trial simulation tool to accelerate trial design in DMD: description of the traphical user interface features and applications R Belfiore-Oshan, V Aggarwal, J Wilk, M Pauley, D Corey, K Romero, ... Neuromuscular Disorders 33, S84, 2023 | | 2023 |
| VP. 85 C-Path's Duchenne Regulatory Science Consortium: Accelerating drug development for Duchenne muscular dystrophy R Belfiore-Oshan, V Aggarwal, S Sivakumaran, D Corey, C Ollivier, ... Neuromuscular Disorders 32, S128, 2022 | | 2022 |
| DMD–BIOMARKERS & OUTCOME MEASURES: P. 126 Development of a regulatory-ready clinical trial simulation tool for Duchenne muscular dystrophy J Larkindale, S Kim, K LIngineni, J Morales, S Schmidt, D Corey, ... Neuromuscular Disorders 30, S83, 2020 | | 2020 |
| MUSCLE IMAGING–MRI: P. 161 Development of clinical trial simulation tools for Duchenne muscular dystrophy using magnetic resonance biomarkers K Vandenborne, S Kim, R Willcocks, J Morales, K Lingineni, A Barnard, ... Neuromuscular Disorders 30, S93-S94, 2020 | | 2020 |
| PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF CLOPIDOGREL AND ITS ACTIVE METABOLITE WHEN ADMINISTERED ALONE OR DURING CONCOMITANT ADMINISTRATION WITH ESOMEPRAZOLE … V Michaud, K Lingineni, J Turgeon, S Schmidt CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S113-S113, 2020 | | 2020 |
| TOWARDS ACHIEVING REGULATORY ENDORSEMENT OF A DISEASE PROGRESSION MODEL-BASED CLINICAL TRIAL SIMULATION TOOL FOR DUCHENNE MUSCULAR DYSTROPHY-MODEL OF PROGRESSION OF FORCED … K Lingineni, D Conrado, D Corey, M Hill, C Vong, J Burton, J Larkindale, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S78-S78, 2020 | | 2020 |
| DEVELOPMENT AND VERIFICATION OF A LEVONORGESTREL PBPK MODEL FOR ENZYME-MEDIATED DRUG INTERACTION STUDIES. B Cicali, R Cristofoletti, T Wendl, K Lingineni, J Hoechel, H Wiesinger, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S64-S64, 2020 | | 2020 |
Prabha GargNational Institute of Pharmaceutical Education and Research, S.A.S. NagarBestätigte E-Mail-Adresse bei niper.ac.in
